AngioDynamics stock slips 4% despite beating estimates on Med Tech growth

AngioDynamics Inc. (NASDAQ:ANGO) reported first quarter fiscal 2027 results on Wednesday, surpassing analyst expectations with an adjusted loss per share of -$0.04, compared to the consensus estimate of -$0.11. The company's revenue grew to $80.9 million, up 6.9% year-over-year, driven by its Med Tech segment, which increased by 13.2% to $39.9 million.

This marks the eighth consecutive quarter of double-digit Med Tech growth. Despite the positive financial performance, AngioDynamics' stock slipped 4.26% in pre-market trading. The company's President and Chief Executive Officer, Jim Clemmer, attributed the results to consistent execution and highlighted the strong performance of the Med Tech segment, led by Auryon's atherectomy growth, Mechanical Thrombectomy, and NanoKnife oncology platform.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.